Diagnostic Imaging

JUNE 28, 2023

In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D.,

Radiopharmaceuticals 58

Radiopharmaceuticals Nuclear Medicine Imaging 58

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 77

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 77

Diagnostic Imaging

JUNE 9, 2024

shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,

Nuclear Medicine 64

Nuclear Medicine Radiopharmaceuticals Diagnostic Imaging 64

Imaging Technology

JUNE 10, 2024

The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.

Nuclear Medicine 84

Nuclear Medicine Radiopharmaceuticals Disease Imaging 84

Imaging Technology

JULY 28, 2023

It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology. POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. Chief Medical Officer of Blue Earth Diagnostics. manufacturer and distributor. “The

Clinic 87

Clinic Diagnostic Radiopharmaceuticals Radiation 87

TTG Imaging Solutions

FEBRUARY 17, 2022

Imaging Conference & Expo: February 20 – 22, 2022 TTG Imaging Solutions will be exhibiting at the Imaging Conference & Expo in Napa, CA. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook. Learn more about TTG in our video overview.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

TTG Imaging Solutions

OCTOBER 20, 2021

The American Society for Radiation Oncology 2021 Annual Meeting: October 24 – 26 TTG Imaging Solutions is proud to be exhibiting at the American Society for Radiation Oncology Annual Meeting in Chicago, IL. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.

Radiation Oncology 52

Radiation Oncology Imaging Radiopharmaceuticals Radiation 52

TTG Imaging Solutions

JANUARY 9, 2022

The American Society of Nuclear Cardiology Cardiac PET Intensive Virtual Workshop: Jan 14 – 16, 2022 TTG Imaging Solutions is proud to sponsor the American Society of Nuclear Cardiology Cardiac PET Intensive Virtual Workshop. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

TTG Imaging Solutions

SEPTEMBER 28, 2021

The American Society of Nuclear Cardiology 2021 Virtual Annual Meeting: September 30 – October 2 TTG Imaging Solutions is proud to be a Bronze Sponsor at the American Society of Nuclear Cardiology Virtual Annual Meeting. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.

Imaging 52

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine 52

TTG Imaging Solutions

OCTOBER 27, 2021

The American Society of Nuclear Cardiology Cardiac PET Advanced Virtual Workshop – Oct 30 & 31, 2021 TTG Imaging Solutions is proud to be a Bronze Sponsor at the American Society of Nuclear Cardiology Cardiac PET Advanced Virtual Workshop. Request a meeting with one of our Regional Sales Managers at sales@ttgimagingsolutions.com.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

Diagnostic Imaging

JANUARY 12, 2024

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

Radiopharmaceuticals 120

Radiopharmaceuticals 120

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Future Teleradiology

NOVEMBER 27, 2023

Teleradiology-India Introduction: Nuclear medicine continues to be at the forefront of cutting-edge technologies, pushing the boundaries of diagnostic and therapeutic capabilities. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation 52

Imaging Technology

JUNE 20, 2024

More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging. In the hands of clinicians, these tools help make the practice of precision care more accessible and aim to help improve patient outcomes globally.”

Healthcare 83

Healthcare Healthcare Nuclear Medicine Computed Tomography 83

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

TTG Imaging Solutions

NOVEMBER 1, 2021

PITTSBURGH, PA (November 1, 2021) – TTG Imaging Solutions, LLC (TTG) announced today executive leadership changes that will drive the company’s next phase of growth following its 9th acquisition in 2 years of Medical Imaging Technologies, an Akron, Ohio based nuclear medicine equipment and service organization.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Medical Imaging 52

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

OCTOBER 5, 2023

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Chief Executive Officer of Blue Earth Diagnostics.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

Radiopharmaceuticals 95

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 95

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., Siegel told AuntMinnie.com. "My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 105

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.

Diagnostic 93

Diagnostic Radiopharmaceuticals Imaging Radiation 93

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical 84

Medical Radiopharmaceuticals Pharmaceutical Radiation 84

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.

Clinic 84

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 84

Future Teleradiology

NOVEMBER 21, 2023

Teleradiology & Radiology data for artificial intelligence (AI) Introduction: Nuclear medicine, a dynamic and rapidly evolving field, continues to break new ground in diagnostic and therapeutic approaches. Highlight how this field merges principles of physics with medical applications for both diagnostic and therapeutic purposes.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Teleradiology 52